sábado, 29 de mayo de 2021

FDA grants accelerated approval to infigratinib for metastatic cholangiocarcinoma | FDA

FDA grants accelerated approval to infigratinib for metastatic cholangiocarcinoma | FDA

No hay comentarios:

Publicar un comentario